ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A seminal paper by Marin et al. reported that BCR-ABL1/ABL1 transcript thresholds of 10% at 3 months and 1% at 6 months strongly predict long-term outcomes for CML patients [23].